
Danilo Menichelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2139746/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Adherence to the â€~Atrial Fibrillation Better Care' Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes—A Systematic Review and Meta-Analysis of 285,000 Patients. Thrombosis and Haemostasis, 2022, 122, 406-414.	3.4	219
2	Oxidative stress and cardiovascular disease: new insights. Kardiologia Polska, 2018, 76, 713-722.	0.6	150
3	Features of severe COVIDâ€19: A systematic review and metaâ€analysis. European Journal of Clinical Investigation, 2020, 50, e13378.	3.4	141
4	Gutâ€Derived Serum Lipopolysaccharide is Associated With Enhanced Risk of Major Adverse Cardiovascular Events in Atrial Fibrillation: Effect of Adherence to Mediterranean Diet. Journal of the American Heart Association, 2017, 6, .	3.7	105
5	Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events. Mayo Clinic Proceedings, 2019, 94, 1261-1267.	3.0	89
6	Seronegative antiphospholipid syndrome: refining the value of "non-criteria―antibodies for diagnosis and clinical management. Haematologica, 2020, 105, 562-572.	3.5	81
7	Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. International Journal of Cardiology, 2018, 264, 58-63.	1.7	69
8	Relationship of PCSK9 and UrinaryÂThromboxane Excretion toÂCardiovascular Events in PatientsÂWithÂAtrial Fibrillation. Journal of the American College of Cardiology, 2017, 70, 1455-1462.	2.8	57
9	Statins and Major Adverse Limb Events in Patients with Peripheral Artery Disease: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2020, 120, 866-875.	3.4	52
10	Agingâ€Related Decline of Glutathione Peroxidase 3 and Risk of Cardiovascular Events in Patients With Atrial Fibrillation. Journal of the American Heart Association, 2016, 5, .	3.7	51
11	Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study. Cancer, 2021, 127, 2122-2129.	4.1	45
12	Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605Â771 patients. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f11-f19.	3.0	40
13	Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines. Frontiers in Cardiovascular Medicine, 2021, 8, 715878.	2.4	39
14	Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. International Journal of Cardiology, 2021, 345, 7-13.	1.7	35
15	Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation. Nutrients, 2020, 12, 3379.	4.1	30
16	Statin liver safety in nonâ€alcoholic fatty liver disease: A systematic review and metanalysis. British Journal of Clinical Pharmacology, 2022, 88, 441-451.	2.4	28
17	Cancer and atrial fibrillation: Epidemiology, mechanisms, and anticoagulation treatment. Progress in Cardiovascular Diseases, 2021, 66, 28-36.	3.1	25
18	Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study. British Journal of Clinical Pharmacology, 2020, 86, 2455-2463.	2.4	24

DANILO MENICHELLI

#	Article	IF	CITATIONS
19	Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding. Pharmacological Research, 2016, 113, 484-489.	7.1	22
20	Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced Liver Disease: An Exploratory Metaâ€Analysis. Hepatology Communications, 2020, 4, 1034-1040.	4.3	22
21	Long-Term Risk of Major Adverse Cardiac Events in Atrial Fibrillation Patients on Direct Oral Anticoagulants. Mayo Clinic Proceedings, 2021, 96, 658-665.	3.0	22
22	Serum albumin and risk of cardiovascular events in primary and secondary prevention: a systematic review of observational studies and Bayesian meta-regression analysis. Internal and Emergency Medicine, 2020, 15, 135-143.	2.0	21
23	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. Internal and Emergency Medicine, 2021, 16, 379-387.	2.0	21
24	Direct oral anticoagulants and advanced liver disease: A systematic review and metaâ€analysis. European Journal of Clinical Investigation, 2021, 51, e13397.	3.4	21
25	The Atrial fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibrillation: a potential sex-based difference. The ATHERO-AF study. European Journal of Internal Medicine, 2021, 85, 80-85.	2.2	21
26	Relationship of Antiphospholipid Antibodies to Risk of Dementia: A Systematic Review. Journal of Alzheimer's Disease, 2019, 69, 561-576.	2.6	20
27	A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients. Frontiers in Pharmacology, 2021, 12, 698008.	3.5	20
28	Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation. European Journal of Internal Medicine, 2018, 54, 34-39.	2.2	18
29	Is There an Interplay Between Adherence to Mediterranean Diet, Antioxidant Status, and Vascular Disease in Atrial Fibrillation Patients?. Antioxidants and Redox Signaling, 2016, 25, 751-755.	5.4	15
30	Determinants of lowâ€quality warfarin anticoagulation in patients with mechanical prosthetic heart valves. The nationwide PLECTRUM study. British Journal of Haematology, 2020, 190, 588-593.	2.5	14
31	Atrial fibrillation pattern, left atrial diameter and risk of cardiovascular events and mortality. A prospective multicenter cohort study. International Journal of Clinical Practice, 2021, 75, e13771.	1.7	14
32	Interaction between serum endotoxemia and proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with atrial fibrillation: A post-hoc analysis from the ATHERO-AF cohort. Atherosclerosis, 2019, 289, 195-200.	0.8	12
33	Comparison of Anticoagulation Quality between Acenocoumarol and Warfarin in Patients with Mechanical Prosthetic Heart Valves: Insights from the Nationwide PLECTRUM Study. Molecules, 2021, 26, 1425.	3.8	12
34	Mediterranean Diet: A Tool to Break the Relationship of Atrial Fibrillation with the Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease. Nutrients, 2022, 14, 1260.	4.1	10
35	Tailored Practical Management of Patients With Atrial Fibrillation: A Risk Factor-Based Approach. Frontiers in Cardiovascular Medicine, 2019, 6, 17.	2.4	8
36	Cancerâ€specific ischemic complications in elderly patients with atrial fibrillation: Data from the prospective ATHEROâ€AF study. International Journal of Cancer, 2020, 147, 3424-3430.	5.1	8

DANILO MENICHELLI

#	Article	IF	CITATIONS
37	Circulating Lipopolysaccharides and Impaired Antioxidant Status in Patients With Atrial Fibrillation. Data From the ATHERO-AF Study. Frontiers in Cardiovascular Medicine, 2021, 8, 779503.	2.4	8
38	Hazelnut and cocoa spread improves flow-mediated dilatation in smokers. Internal and Emergency Medicine, 2018, 13, 1211-1217.	2.0	7
39	Silybin and metabolic disorders. Internal and Emergency Medicine, 2019, 14, 1-3.	2.0	7
40	Update and Unmet Needs on the Use of Nonvitamin K Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation. Current Problems in Cardiology, 2021, 46, 100410.	2.4	7
41	Fibrosis-4 (FIB-4) Index and mortality in COVID-19 patients admitted to the emergency department. Internal and Emergency Medicine, 2022, 17, 1777-1784.	2.0	7
42	Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. Data in Brief, 2018, 17, 830-836.	1.0	5
43	Relation of Atrial Fibrillation to Angiographic Characteristics and Coronary Artery Disease Severity in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2021, 141, 1-6.	1.6	5
44	Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study. Internal and Emergency Medicine, 2021, 16, 2063-2068.	2.0	5
45	Clinical Phenotypes of Atrial Fibrillation and Mortality Risk—A Cluster Analysis from the Nationwide Italian START Registry. Journal of Personalized Medicine, 2022, 12, 785.	2.5	4
46	Family History of Atrial Fibrillation and Risk of Cardiovascular Events. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008477.	4.8	3
47	Serum albumin, clotting activation and COVID-19 severity: a systematic review and meta-regression analysis of 4579 patients. Italian Journal of Emergency Medicine, 2021, 10, .	0.1	3
48	Sexâ€based difference in anticoagulated patients with mechanical prosthetic heart valves and longâ€ŧerm mortality risk. International Journal of Clinical Practice, 2021, 75, e14064.	1.7	1
49	Multiple Arterial Thrombosis in Seronegative Antiphospholipid Syndrome: Need for New Diagnostic Criteria?. European Journal of Case Reports in Internal Medicine, 2019, 6, 1.	0.4	1
50	Bleeding and mortality risk in patients implanted with mechanical prosthetic heart valves with and without thrombocytopenia. Insights from the nationwide PLECTRUM registry. Platelets, 2022, , 1-6.	2.3	0